AzTrials
AzTrials

Jaundice NeonatalNCT02625688

The Risk of Hyperbilirubinemia in Term Newborns After Placental Transfusion

A study testing Delayed cord clamping, Cord milking and Early cord clamping in people with Jaundice Neonatal, run by Princess Anna Mazowiecka Hospital, Warsaw, Poland at 1 site in Poland.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Delayed cord clamping (DCC) has been a subject of extensive research for the last couple of years. Based on published data, numerous neonatal benefits have been suggested such as increased hemoglobin and ferritin levels both at birth and longer term. Read more about this study

Who is it for?
Ages 37 to 42 weeks
Conditions the study is for
Jaundice Neonatal
What is being tested?
Delayed cord clamping, Cord milking and Early cord clamping
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
400 participants
Where
1 sitePoland
Study dates
Aug 2013to Dec 2016
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 37 to 42 weeks
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • All maternal-fetal dyads must comply with all of the following at randomization:
  • Term delivery between 37 -42 weeks of gestation (estimated by ultrasound).
  • Signed parental consent.
  • Singleton delivery.
  • Nonsmoking mothers.
  • Mothers willing to return for follow up visits.
Show all 17Show fewer
  • Declaration of breastfeeding for at least six months.
  • Exclusion Criteria The following maternal - fetal dyads will be excluded
  • Preterm delivery < 37 weeks of gestation (estimated by ultrasound).
  • Isoimmune hemolytic disease.
  • Sepsis.
  • Maternal Gilbert syndrome.
  • Birth asphyxia.
  • Serious maternal hemorrhage during delivery.
  • Major congenital abnormalities.
  • Need for early cord clamping (tight nuchal cord, need for resuscitation).
  • Participation in another trial.

Who cannot join

None listed.

Trial locations and contacts

1 site in 1 country.

Poland1 site
  • Department of Neonatology and Neonatal Intensive Care Warsaw Medical University

    Warsaw, 00-315

Other trials in Poland

About this study

Official title: The Risk of Hyperbilirubinemia in Term Newborns After Placental Transfusion: A Randomized-blinded Controlled Trial

Delayed cord clamping (DCC) has been a subject of extensive research for the last couple of years. Based on published data, numerous neonatal benefits have been suggested such as increased hemoglobin and ferritin levels both at birth and longer term. Available systematic reviews of DCC versus early cord clamping (ECC) reveal that it may also contribute to other neonatal outcomes including polycythemia and hyperbilirubinemia.

A review published nearly 10 years ago regarding late umbilical cord clamping revealed only 4 studies which as a second objective assessed whether the time of cord clamping was associated with an increased risk of polycythemia and hyperbilirubinemia during the first week of life. Two studies reported that neonates with DCC had bilirubin levels >15 mg/dl. No information is provided on what hour of life the bilirubin levels were measured exactly.

In this randomized control study the investigators would like to determine if delayed cord clamping or cord milking during labor increases the risk of hyperbilirubinaemia (requiring phototherapy) in term infants.

Read the detailed description

The investigators feel that published results regarding 'jaundice" and "jaundice needing phototherapy' (associated with DCC) may be misleading.

First, no information is offered about how "clinical jaundice "was assessed on examination. The absence of jaundice is not an indication of the absence of hyperbilirubinemia. Estimation of the degree of hyperbilirubinemia based solely on clinical examination can lead to errors. The absence or the severity of jaundice is not predictive of subsequent severe hyperbilirubinemia. A recent study revealed that the nurses' predischarge assessment of jaundice extent was only moderately correlated with bilirubin concentration and was similar in black and nonblack infants.

A review published nearly 10 years ago regarding late umbilical cord clamping revealed only 4 studies which as a secondary objective which assessed whether the time of cord clamping was associated with an increased risk of polycythemia and hyperbilirubinemia during the first week of life. Two studies reported that neonates with DCC had bilirubin levels >15 mg/dl. No information is provided on what hour of life the bilirubin levels were measured exactly.

Secondly, guidelines to treat jaundice have changed over time and none of the studies mention what threshold was used for administering phototherapy. No information is given if, staff responsible for phototherapy administration was blinded to the type of cord clamping intervention. Potential confounders such as isoimmune hemolytic disease, symptoms of sepsis (significant lethargy, temperature instability), asphyxia, G6PD, acidosis, albumin <3 g/L were not included in the analysis. Also another important factor such feeding policy at the time of bilirubin measurement wasn't mentioned in neither of the studies.

The presence of all mentioned above confounders in available studies has lead the investigators to conduct a blinded randomized trial.

Postnatal hyperbilirubinemia is universal and manifests as newborn jaundice in over 60-80% of all newborns. If left untreated hyperbilirubinemia may progress to excessive levels that can be associated with evident bilirubin neurotoxicity. Jaundice is the most common clinical diagnosis in neonatal medicine. Elevated bilirubin concentrations may occur due to increased bilirubin production (breakdown of heme moiety of hemoglobin) and/or delayed bilirubin elimination (hepatic and intestinal) as well as by a unique neonatal phenomenon of enterohepatic reabsorption of bilirubin.

Studies have shown that late cord clamping benefits expand beyond the neonatal period. A meta -analyses estimated a significant 47% reduction in the risk of anemia and 33% reduction in risk of having deficient iron stores at ages 2 to 3 months in the delayed cord clamping group. These pooled results are based on two small studies, and despite a significant number of patients lost to follow up (40%), these results agree with a large randomized trial.

It is important to understand whether evidence based benefits of DCC (such as increase of hemoglobin, improved iron status, and decreased risk of infant anemia) may also contribute to less favorable neonatal outcomes. This trial will aim to assess if delayed cord clamping truly increases the risk of hyperbilirubinaemia requiring phototherapy or even exchange transfusion.

Dose selection:

The total feto-placental blood volume is about 120 ml/kg of fetal weight. At birth, the distribution of blood between fetus and placenta is roughly at a ratio of 2:1. Increasing placental transfusion to at least three minutes leads to a larger infant blood volume (ratio 5:1).The rate of placental transfusion is markedly influenced by the position of the delivered infant. From at least 10 cm above to at least 10 cm below the level of the placenta, infants receive the maximum possible amount after at least three minutes of birth .

The randomized and quasi-randomized controlled trials that studied delayed cord clamping in vaginally born, healthy, term infants differed in clamping time and infant position before clamping and there is still no consensus about the time required for a sufficient amount of blood to be transfused from the placenta to the baby. The above mentioned trials showed that placental-neonate blood flow significantly increases after DCC by showing higher packed cell volume or hemoglobin concentration in the first 24 hours after birth compared with immediate clamping.

To test the hypothesis, investigators have decided to delay cord clamping in the intervention group to 3 minutes and place the baby 10 cm above the placental, as it seems most efficient based on the available literature. At all births (spontaneous vaginal deliveries and caesarian sections) a member of the recruitment team will be present. He will inform the midwife or obstetrician about the allocated intervention and measure the time from the delivery of the shoulders to the cord clamping. If cord milking will be the allocated intervention, the recruiter will supervise the midwife, or obstetrician preforming the procedure, and count out loud the number of times the cord has been milked. During vaginal deliveries midwifes will be asked to maintain the infant at least 10 cm above the uterus until the cord is clamped. In case of caesarian sections the baby will be placed on the mother's laps and swaddled in sterile towels to prevent heat loss. In the early cord clamping group, the recruiter will inform the midwife or obstetrician when 30 seconds have passed. In the delayed clamping group, the recruiter will inform the midwife or obstetrician after 3 minutes.

If cord milking will be applied the baby will be placed below the level of the placenta, between the mother's thighs (during a vaginal delivery) or at the side of the mother swaddled in sterile towels (during a caesarian delivery). Based on available literature, before starting the trial investigators piloted this procedure[13]. They checked that about two thirds of the umbilical cord will be present for milking both during a vaginal and caesarian delivery. If the cord was milked once we were able to transfer approximately 10 ml of blood to the neonate. Following this, and under the assumption that the cord vein will be rapidly refilling itself, investigators assume that milking the cord four times will give us 40 ml of blood [13]. A member of the delivery team (vaginal delivery) or operating team (caesarian delivery) will hold the cord at the level of the introitus or cesarean wound, and milk the cord four times towards the neonate counting out loud. The cord will be clamped after the forth milking.

Choice of comparator In spite of available studies which advocate for delayed cord clamping, it is still infrequently used in labor wards throughout the world[28]. According to the new guidelines early cord clamping-ECC is defined as cord clamping at less than 60 seconds after the delivery. The available meta-analyses comparing early versus late cord clamping include studies which significantly vary in defining ECC. The majority of trials define ECC as clamping within the first 10 seconds, other describe ECC as immediate clamping. Only one trial extended ECC to be as long as 60 seconds.

The new 2010 ILCOR (International Liaison Committee on Resuscitation) guidelines advocate for DDC, stating that cord clamping should be delayed for at least 1 min from the complete delivery of the baby. Investigators have chosen this definition, as the ILCOR committee provides an international consensus and evidence based guidelines on emergency care, which are widely accepted among neonatologist throughout the world.

ECC is part of active management of labour. Active management usually involves the clinician intervening in the process through three interrelated processes: the administration of a prophylactic uterotonic drug; cord clamping and cutting at ≤60 seconds after delivery; and controlled traction of the umbilical cord. These interventions are aimed at reduction in the risk of postpartum haemorrhage. However, ECC eliminates the possibility of additional blood flowing from the placenta to the newborn, and deprives the baby from numerous profits such as receiving extra amounts of iron. This potential additional amount of iron prevents iron deficiency during the first year of life in infants born with delayed cord clamping.

Research Hypothesis Neither delayed cord clamping nor cord milking during labor does not increase significantly the risk of hyperbilirubinaemia in comparison to early cord clamping.

Description of trial design The trail is designed as a randomized controlled, observer blinded trial with 3 parallel groups and a primary endpoint of hyperbilirubinemia requiring phototherapy. Randomization will be performed as block randomization with a 1:1:1 allocation. The experiment is designed to demonstrate non-inferiority of delayed cord clamping and cord milking group in comparison to early cord clamping group regarding the incidence of bilirubinemia treated with phototherapy in neonates.

Description of study settings The study will be carried out in the Princess Anne's Hospital in Warsaw, Poland. This is a level III teaching hospital with approximately 3500 (1000 < 37 weeks of gestation) deliveries per year and 63 neonatal beds. It is also a referral center for gestational and pre-gestational diabetes as well as pregnancy induced hypertension. Having access to high risk mothers will augment the population of small for gestation infants (SGA), and infants of diabetic mothers (IDM) in the study. SGA and IDM have an increased risk for hyperbilirubinemia, thus the presence of the above patients will improve the generalizability of the study population. The local protocol on cord clamping has not yet been adjusted to the new ILCOR guidelines, but labour ward staff are willing to implement new procedures. This should improve trail recruitment and adherence.

Being tested
Delayed cord clamping, Cord milking, Early cord clamping
Medical subject headings
Jaundice, Neonatal

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Delayed cord clampingOther

    We have decided to delay cord clamping in the intervention group to 3 minutes and place the baby 10 cm above the placental, as it seems most efficient based on the available literature. At all births (spontaneous vaginal deliveries and caesarian sections) a member of the recruitment team will be present. He will inform the midwife or obstetrician about the allocated intervention and measure the time from the delivery of the shoulders to the cord clamping.

  • Cord milkingOther

    If cord milking will be the allocated intervention, the recruiter will supervise the midwife, or obstetrician preforming the procedure, and count out loud the number of times the cord has been milked. During vaginal deliveries midwifes will be asked to maintain the infant at least 10 cm above the uterus until the cord is clamped. In case of caesarian sections the baby will be placed on the mother's laps and swaddled in sterile towels to prevent heat loss.

  • Early cord clampingOther

    We have decided to clamp the cord in the early intervention group at 30 seconds and place the baby 10 cm above the placental, as it seems most efficient based on the available literature. At all births (spontaneous vaginal deliveries and caesarian sections) a member of the recruitment team will be present. He will inform the midwife or obstetrician about the allocated intervention and measure the time from the delivery of the shoulders to the cord clamping.

Study groups in NCT02625688
Study groupRoleWhat they receive
Early cord clampingPlacebo comparatorCord clamping will be applied after 30 seconds post delivery.
Receives: Other: Early cord clamping
Delayed cord clampingActive comparatorCord clamping will be applied after 3 minutes post delivery.
Receives: Other: Delayed cord clamping
Cord milkingActive comparatorThe baby will be placed below the level of the placenta, between the mother's thighs (during a vaginal delivery) or at the side of the mother swaddled in sterile towels (during a caesarian delivery).
Receives: Other: Cord milking

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The number of patients with hyperbilirubinemia requiring phototherapy or exchange transfusion.

    Infants requiring phototherapy or exchange transfusion will be evaluated according to the AAP guidelines. The above evidence based guidelines describe the management of neonatal hyperbilirubinaemia in newborns above 35 weeks of gestation. Serum bilirubin levels will be interpreted according to the baby's age in hours. Physicians assessing the infant and prescribing phototherapy will be blinded to treatment.

    Measured: 14 days of life

Secondary outcomes (4)
  1. The number of patients with polycythemia defined as a hematocrit > 65%.

    Hematocrit levels peak at about 2 hours of age, and gradually stabilize during the following 12-24 hours. To avoid bias and minimalize the amount of needle pricks we have chosen to combine serum bilirubin and hematological measurements to the minimal amount of samples .

    Measured: 48-72 hours of life.

  2. The number of patients with symptomatic polycythemia (hematocrit > 75%), and non - symptomatic polycythemia (hematocrit >80%).

    Symptomatic polycythemia (hematocrit > 75%), non - symptomatic polycythemia (hematocrit >80%) requiring exchange transfusion during the 48-72 hours of life

    Measured: 48-72 hours of life

  3. The number of patients with symptomatic polycythemia defined as lethargy, plethora, jitteriness, tachycardia, tachypnea

    Measured: 48-72 hours of life

  4. The number of patients with congenital anemia

    cord Hb <12.5 g/dL

    Measured: at birth

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Dec 2015 (estimated)
  2. Study startAug 2013
  3. Primary completionJun 2016
  4. Study completionDec 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
400 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02625688
Sponsor's protocol ID
1/2013
Status last verified
Mar 2017
First submitted
26 Nov 2015
Last updated
28 Mar 2017
Results posted
No
Data monitoring committee
No

Publications

  • Bhutani VK, Gourley GR, Adler S, Kreamer B, Dalin C, Johnson LH. Noninvasive measurement of total serum bilirubin in a multiracial predischarge newborn population to assess the risk of severe hyperbilirubinemia. Pediatrics. 2000 Aug;106(2):E17. doi: 10.1542/peds.106.2.e17.

    PubMed 10920173
  • Rubaltelli FF, Gourley GR, Loskamp N, Modi N, Roth-Kleiner M, Sender A, Vert P. Transcutaneous bilirubin measurement: a multicenter evaluation of a new device. Pediatrics. 2001 Jun;107(6):1264-71. doi: 10.1542/peds.107.6.1264.

    PubMed 11389241
  • Bhutani VK, Johnson L, Sivieri EM. Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. Pediatrics. 1999 Jan;103(1):6-14. doi: 10.1542/peds.103.1.6.

    PubMed 9917432
  • Keren R, Tremont K, Luan X, Cnaan A. Visual assessment of jaundice in term and late preterm infants. Arch Dis Child Fetal Neonatal Ed. 2009 Sep;94(5):F317-22. doi: 10.1136/adc.2008.150714. Epub 2009 Mar 22.

    PubMed 19307221
  • McDonald SJ, Middleton P. Effect of timing of umbilical cord clamping of term infants on maternal and neonatal outcomes. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD004074. doi: 10.1002/14651858.CD004074.pub2.

    PubMed 18425897
  • Gupta R, Ramji S. Effect of delayed cord clamping on iron stores in infants born to anemic mothers: a randomized controlled trial. Indian Pediatr. 2002 Feb;39(2):130-5.

    PubMed 11867842
  • Ceriani, R.J., Ferreira C. P. , M. A., Effect of Timing of Cord Clamping on Postnatal Hematocrit Values and Clinical Outcome in Term Infants. A Randomized, Controlled Trial. Pediatr Res, 2005. 57(6): p. 922-922.

  • Bhutani, V.K., Screening for severe neonatal hyperbilirubinemia. Pediatric Health, 2009. 3(4): p. 369-379.

Questions about this trial

What is this clinical trial studying?

A study testing Delayed cord clamping, Cord milking and Early cord clamping in people with Jaundice Neonatal, run by Princess Anna Mazowiecka Hospital, Warsaw, Poland at 1 site in Poland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 17 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Mar 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Poland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The number of patients with hyperbilirubinemia requiring phototherapy or exchange transfusion. (time frame: 14 days of life). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02625688, which also lists 8 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Mar 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in